About InVision Medical Technology

InVision develops AI technologies for the analysis of cardiac ultrasounds, enabling the detection of previously unidentified cardiovascular conditions. This technology enhances diagnostic accuracy and improves patient outcomes by providing healthcare professionals with actionable insights from ultrasound data.

```xml <problem> The interpretation of cardiac ultrasound images is often subjective and time-consuming, potentially leading to missed or delayed diagnoses of cardiovascular conditions. Detecting subtle indicators of diseases like cardiac amyloidosis can be particularly challenging, requiring specialized expertise and increasing the risk of inter-observer variability. </problem> <solution> InVision Medical Technology develops AI-powered tools to analyze cardiac ultrasound data, assisting clinicians in the early and accurate detection of cardiovascular diseases. Their technology applies machine learning algorithms to identify subtle patterns and anomalies in ultrasound images that may be indicative of conditions such as cardiac amyloidosis. By providing quantitative measurements and automated analysis, InVision aims to improve diagnostic accuracy, reduce variability, and enable earlier intervention for patients with cardiovascular conditions. The platform integrates into existing clinical workflows, providing actionable insights directly to healthcare professionals. </solution> <features> - AI-powered analysis of cardiac ultrasound images for enhanced detection of cardiovascular conditions - FDA-cleared algorithms for the detection of Cardiac Amyloidosis and Precision LVEF (Left Ventricular Ejection Fraction) - Quantitative measurements and automated reporting to reduce subjective interpretation - Integration with existing clinical workflows and electronic health record (EHR) systems - DICOM de-identification tools to ensure patient data privacy and security </features> <target_audience> The primary target audience includes cardiologists, radiologists, and other healthcare professionals involved in the diagnosis and management of cardiovascular diseases, as well as hospitals and imaging centers. </target_audience> ```

What does InVision Medical Technology do?

Where is InVision Medical Technology located?

InVision Medical Technology is based in Los Angeles, United States.

When was InVision Medical Technology founded?

InVision Medical Technology was founded in 2022.

Location

Los Angeles, United States

Founded

2022

Looking for specific startups?

Try our free semantic startup search

InVision Medical Technology

AI-Generated Company Overview (experimental) – could contain errors

Executive Summary

invisionmedtech.com

Founded 2022 – Los Angeles, United States

Funding

No funding information available. Click "Fetch funding" to run a targeted funding scan.

Company Description

Problem

The interpretation of cardiac ultrasound images is often subjective and time-consuming, potentially leading to missed or delayed diagnoses of cardiovascular conditions. Detecting subtle indicators of diseases like cardiac amyloidosis can be particularly challenging, requiring specialized expertise and increasing the risk of inter-observer variability.

Solution

InVision Medical Technology develops AI-powered tools to analyze cardiac ultrasound data, assisting clinicians in the early and accurate detection of cardiovascular diseases. Their technology applies machine learning algorithms to identify subtle patterns and anomalies in ultrasound images that may be indicative of conditions such as cardiac amyloidosis. By providing quantitative measurements and automated analysis, InVision aims to improve diagnostic accuracy, reduce variability, and enable earlier intervention for patients with cardiovascular conditions. The platform integrates into existing clinical workflows, providing actionable insights directly to healthcare professionals.

Features

AI-powered analysis of cardiac ultrasound images for enhanced detection of cardiovascular conditions

FDA-cleared algorithms for the detection of Cardiac Amyloidosis and Precision LVEF (Left Ventricular Ejection Fraction)

Quantitative measurements and automated reporting to reduce subjective interpretation

Integration with existing clinical workflows and electronic health record (EHR) systems

DICOM de-identification tools to ensure patient data privacy and security

Target Audience

The primary target audience includes cardiologists, radiologists, and other healthcare professionals involved in the diagnosis and management of cardiovascular diseases, as well as hospitals and imaging centers.